17R Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Regulatory Milestone: FSGS ApprovalBeing the first and only FDA‑approved therapy for FSGS materially expands Travere's durable addressable market and clinical positioning. The approval opens >30,000 U.S. FSGS patients (and >100,000 total across IgA/FSGS), strengthening payer negotiations and long‑term uptake dynamics.
Strong Commercial Traction & Payer AccessSustained high prescription starts, steep YoY growth and established payer access (~97%) indicate robust commercial execution. These durable commercial capabilities support predictable revenue scaling, reduce launch friction for new indications, and improve the odds of converting eligible patients into long‑term users.
Pipeline Expansion Via Civorebrutinib LicenseThe exclusive license broadens Travere's kidney‑disease R&D footprint with a novel BTK asset, diversifying future revenue levers and indication coverage. This structural deal adds late‑stage development optionality and a strategic 10‑year non‑compete, supporting long‑term franchise building despite added obligations.
Bears Say
Elevated LeverageHigh debt relative to equity constrains financial flexibility and increases refinancing and interest risk over time. Even after recent refinancings, leverage limits capacity for opportunistic M&A, higher R&D spend without dilutive financing, and makes operating cash flow consistency critical for balance‑sheet stability.
Ongoing GAAP Losses And Rising Operating CostsMaterial increases in R&D and SG&A to support launches and trials raise the break‑even threshold. Continued GAAP losses mean profitability depends on sustained FILSPARI growth and successful pipeline outcomes; if revenue growth slows, elevated fixed costs could pressure margins and cash generation.
Pipeline Execution And Competitive RiskKey pipeline readouts (eg, HARMONY in 2027) and commercialization of new indications carry execution and regulatory risk. Simultaneous entrants in IgA nephropathy and uncertainties around clinical timelines could limit peak penetration and extend the time required to realize modeled revenues.
Travere Therapeutics News
17R FAQ
What was Travere Therapeutics, Inc.’s price range in the past 12 months?
Currently, no data Available
What is Travere Therapeutics, Inc.’s market cap?
Travere Therapeutics, Inc.’s market cap is CHF4.26B.
When is Travere Therapeutics, Inc.’s upcoming earnings report date?
Travere Therapeutics, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 23 days.
How were Travere Therapeutics, Inc.’s earnings last quarter?
Travere Therapeutics, Inc. released its earnings results on May 04, 2026. The company reported -$0.322 earnings per share for the quarter, missing the consensus estimate of -$0.195 by -$0.127.
Is Travere Therapeutics, Inc. overvalued?
According to Wall Street analysts Travere Therapeutics, Inc.’s price is currently Undervalued.
Does Travere Therapeutics, Inc. pay dividends?
Travere Therapeutics, Inc. does not currently pay dividends.
What is Travere Therapeutics, Inc.’s EPS estimate?
Travere Therapeutics, Inc.’s EPS estimate is -0.07.
How many shares outstanding does Travere Therapeutics, Inc. have?
Currently, no data Available
What happened to Travere Therapeutics, Inc.’s price movement after its last earnings report?
Travere Therapeutics, Inc. reported an EPS of -$0.322 in its last earnings report, missing expectations of -$0.195. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Travere Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CH:17R
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Travere Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
283.55%
12-Months-Change
Fundamentals
Return on Equity
-26.79%
Trailing 12-Months
Asset Growth
1.16%
Trailing 12-Months
Company Description
Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical firm headquartered in San Diego, California, was founded in 2008 with a mission to discover, develop, commercialize, and deliver treatments for rare diseases. The company adopted its current name in November 2020, previously operating as Retrophin, Inc. Its current product offerings include Chenodal, an orally administered synthetic form of chenodeoxycholic acid, used to dissolve radiolucent gallstones. Another key product is Cholbam, a cholic acid capsule prescribed for both children and adults suffering from bile acid synthesis disorders stemming from single enzyme defects, and as an auxiliary treatment for peroxisomal disorders. Additionally, Thiola and Thiola EC, tiopronin tablets, are available for managing homozygous cystinuria. In its development pipeline, Travere is advancing several therapeutic candidates. Sparsentan is currently in Phase III clinical trials, being investigated for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. Also under development is TVT-058, a pioneering investigational human enzyme replacement candidate, which is undergoing Phase I/II clinical trials for classical homocystinuria. The company actively engages in strategic partnerships, holding a cooperative research and development agreement with the National Institutes of Health's National Center for Advancing Translational Sciences. It also collaborates with patient advocacy groups such as CDG Care and the Alagille Syndrome Alliance, collectively working towards identifying potential small molecule therapies for NGLY1 deficiency and Alagille syndrome.
17R Company Deck
17R Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive commercial and clinical momentum: a landmark FDA approval in FSGS, record demand and an 88% YoY increase in FILSPARI sales, encouraging pipeline progress (HARMONY restart with 2027 readout expectation), and improved non-GAAP profitability. Offsetting these positives are significant near-term cost increases (R&D and SG&A), higher royalty expense due to accounting changes, a continuing GAAP net loss, and some short-term revenue recognition/timing headwinds and education needs with physicians and payers. Overall, the positives (major approval, large sales growth, record demand, and clear runway to advance the pipeline) outweigh the near-term financial and operational challenges.View all CH:17R earnings summaries17R Stock 12 Month Forecast
Average Price Target
$47.18
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Options Prices
Currently, No data available
---